Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) stock fell -0.35% on Friday to $8.57 against a previous-day closing price of $8.60. With 17.54 million shares changed hands, the volume of the stock remained heavier than its average volume of 6.28 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.72 whereas the lowest price it dropped to was $8.36. The 52-week range on RXRX shows that it touched its highest point at $16.75 and its lowest point at $4.54 during that stretch. It currently has a 1-year price target of $16.83. Beta for the stock currently stands at -0.05.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RXRX was up-trending over the past week, with a rise of 6.33%, but this was down by -1.49% over a month. Three-month performance dropped to -7.85% while six-month performance rose 12.03%. The stock lost -36.38% in the past year, while it has gained 11.15% so far this year. A look at the trailing 12-month EPS for RXRX yields -1.39 with Next year EPS estimates of -1.65. For the next quarter, that number is -0.39. This implies an EPS growth rate of 8.30% for this year and -13.00% for next year.
Float and Shares Shorts:
At present, 196.56 million RXRX shares are outstanding with a float of 183.67 million shares on hand for trading. On Aug 30, 2023, short shares totaled 23.04 million, which was 10.89% higher than short shares on Jul 30, 2023. In addition to Dr. Christopher C. Gibson Ph.D. as the firm’s Co-Founder, CEO & Director, Ms. Tina Marriott Larson serves as its COO & Pres.
Other institutions hold 35.13% of RXRX, in contrast to 23.41% held by mutual funds. Shares owned by individuals account for 19.07%. As the largest shareholder in RXRX with 12.30% of the stake, Baillie Gifford & Co. holds 25,097,630 shares worth 25,097,630. A second-largest stockholder of RXRX, The Vanguard Group, Inc., holds 11,032,410 shares, controlling over 5.41% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in RXRX, holding 9,492,506 shares or 4.65% stake. With a 7.86% stake in RXRX, the Scottish Mortgage Investment Trus is the largest stakeholder. A total of 16,029,227 shares are owned by the mutual fund manager. The ARK Genomic Revolution ETF, which owns about 3.05% of RXRX stock, is the second-largest Mutual Fund holder. It holds 6,226,753 shares valued at 54.17 million. Government Pension Fund – Global holds 2.14% of the stake in RXRX, owning 4,371,313 shares worth 38.03 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, RXRX reported revenue of $7.65M and operating income of -$66.19M. The EBITDA in the recently reported quarter was -$62.76M and diluted EPS was -$0.38.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RXRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With RXRX analysts setting a high price target of $35.00 and a low target of $9.00, the average target price over the next 12 months is $16.00. Based on these targets, RXRX could surge 308.4% to reach the target high and rise by 5.02% to reach the target low. Reaching the average price target will result in a growth of 86.7% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded RXRX stock several times over the past three months with 15 Buys and 31 Sells. In these transactions, 286,453 shares were bought while 453,765 shares were sold. The number of buy transactions has increased to 96 while that of sell transactions has risen to 95 over the past year. The total number of shares bought during that period was 5,784,947 while 1,089,901 shares were sold.